Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Revenue of Standard BioTools Inc. (LAB)
Revenue in 2023 (TTM): $106.34 M
According to Standard BioTools Inc.'s latest financial reports the company's current revenue (TTM) is $106.34 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Standard BioTools Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $106.34 M | $50.45 M | $-54,457,000 | $-74,204,000 | $-74,656,000 |
| 2022 | $97.95 M | $37.05 M | $-173,570,000 | $-192,928,000 | $-190,098,000 |
| 2021 | $130.58 M | $69.37 M | $-43,769,000 | $-63,660,000 | $-59,237,000 |
| 2020 | $138.14 M | $83.33 M | $-34,605,000 | $-54,101,000 | $-53,020,000 |
| 2019 | $117.24 M | $64.28 M | $-46,621,000 | $-66,705,000 | $-64,790,000 |
| 2018 | $112.96 M | $61.65 M | $-31,027,000 | $-61,420,000 | $-59,013,000 |
| 2017 | $101.94 M | $51.98 M | $-39,675,000 | $-63,799,000 | $-60,535,000 |
| 2016 | $104.45 M | $58.44 M | $-56,419,000 | $-80,177,000 | $-75,985,000 |
| 2015 | $114.71 M | $68.08 M | $-32,867,000 | $-54,790,000 | $-53,315,000 |
| 2014 | $116.46 M | $73.61 M | $-38,500,000 | $-57,705,000 | $-52,830,000 |
| 2013 | $71.18 M | $51.1 M | $-13,824,000 | $-15,685,000 | $-15,822,000 |
| 2012 | $52.33 M | $37.01 M | $-16,778,000 | $-18,888,000 | $-19,024,000 |
| 2011 | $42.87 M | $29.67 M | $-18,141,000 | $-22,304,000 | $-22,470,000 |
| 2010 | $33.56 M | $21.98 M | $-13,521,000 | $-16,819,000 | $-16,902,000 |
| 2009 | $25.41 M | $13.93 M | $-14,670,000 | $-19,178,000 | $-19,128,000 |
| 2008 | $15.35 M | $6.98 M | $-26,118,000 | $-29,646,000 | $-29,499,000 |
| 2007 | $7.28 M | $3.76 M | $-20,913,000 | $-25,346,000 | $-25,451,000 |
| 2006 | $6.4 M | $3.63 M | $-19,833,000 | $-23,553,000 | $-23,553,000 |
| 2001 | $130.58 M | $77.27 M | $-67,459,000 | $-63,660,000 | $-59,237,000 |